These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 30167331)

  • 1. CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion.
    Preusser M; De Mattos-Arruda L; Thill M; Criscitiello C; Bartsch R; Ruhstaller T; de Azambuja E; Zielinski CC
    ESMO Open; 2018; 3(5):e000368. PubMed ID: 30167331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
    Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
    Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
    Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
    Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an
    Awada A; Gligorov J; Jerusalem G; Preusser M; Singer C; Zielinski C
    ESMO Open; 2019; 4(6):e000565. PubMed ID: 31798979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Kwapisz D
    Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
    Spring LM; Zangardi ML; Moy B; Bardia A
    Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
    Cersosimo RJ
    Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
    Eggersmann TK; Degenhardt T; Gluz O; Wuerstlein R; Harbeck N
    BioDrugs; 2019 Apr; 33(2):125-135. PubMed ID: 30847853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Laderian B; Fojo T
    Semin Oncol; 2017 Dec; 44(6):395-403. PubMed ID: 29935901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
    Parylo S; Vennepureddy A; Dhar V; Patibandla P; Sokoloff A
    J Oncol Pharm Pract; 2019 Jan; 25(1):110-129. PubMed ID: 29726787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer.
    George MA; Qureshi S; Omene C; Toppmeyer DL; Ganesan S
    Front Oncol; 2021; 11():693104. PubMed ID: 34327137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 Inhibitors.
    O'Sullivan CC
    Int J Cancer Clin Res; 2015; 2(4):. PubMed ID: 26726315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.
    van Ommen-Nijhof A; Konings IR; van Zeijl CJJ; Uyl-de Groot CA; van der Noort V; Jager A; Sonke GS;
    BMC Cancer; 2018 Nov; 18(1):1146. PubMed ID: 30458732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in pharmacotherapies that target the cell cycle for treatment of breast cancer: where are we at today?
    Perrone M; Giuliani F; Sanna V; Bruno S; Melaccio A; Santoro AN; Laface C; Maselli FM; Iaia ML; Guarini C; Fancellu A; Fedele P
    Expert Opin Pharmacother; 2023 Jun; 24(8):887-900. PubMed ID: 37038927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer.
    Shah AN; Cristofanilli M
    Curr Treat Options Oncol; 2017 Jan; 18(1):6. PubMed ID: 28197838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting CDK4/6 pathways and beyond in breast cancer.
    Ribnikar D; Volovat SR; Cardoso F
    Breast; 2019 Feb; 43():8-17. PubMed ID: 30359883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Latest Overview of the Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: The Past, the Present and the Future.
    Chen X; Xu D; Li X; Zhang J; Xu W; Hou J; Zhang W; Tang J
    J Cancer; 2019; 10(26):6608-6617. PubMed ID: 31777590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update.
    O'Sullivan CC
    Expert Opin Pharmacother; 2016 Aug; 17(12):1657-67. PubMed ID: 27322766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer.
    Barroso-Sousa R; Shapiro GI; Tolaney SM
    Breast Care (Basel); 2016 Jun; 11(3):167-73. PubMed ID: 27493615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDK4/6 inhibition in early and metastatic breast cancer: A review.
    de Groot AF; Kuijpers CJ; Kroep JR
    Cancer Treat Rev; 2017 Nov; 60():130-138. PubMed ID: 28961554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.